commercial-strategy
(10)
Rick Green Makes Complicated Technology Make Sense
Across medical robotics, life science, pharmacy automation and patient-engagement software, Rick Green has kept returning to the same deceptively hard assignment: turn an intricate system into a story people can use.
Andy Orth Knows the Hard Part Comes After the Breakthrough
The City Therapeutics CEO has spent a career translating new science into organizations that can move - with a bias for shared purpose, quick decisions and the unglamorous work that follows discovery.
Jaymie Heil Thinks a Business Should Ride Like a Bicycle
After decades selling fireplaces, grills and outdoor-living products across borders, Jaymie Heil has reduced commercial strategy to a surprisingly human idea: keep the promise and the delivery in balance.
Thomas Han Built a Biotech Career at the Hand-Off
Thomas Han spent decades learning how medicines move from a promising idea to a durable business. At Peroxitech, he is applying that education to the hardest hand-off in biotech: turning university science into a company that can keep moving.
Cristy Simon Is Building the Commercial Language for a 160-Year-Old Company
After years translating medical technology for global markets, Cristy Simon took on a different kind of brief: give a sprawling, purpose-led organization a commercial strategy its people can actually use.
Amy Mahery Learned the Business by Moving Toward the Hard Parts
Her career began with a rugby conversation in an airport lounge. Two decades later, the Moderna marketing chief still treats curiosity, range and access to information as operating tools.
Mike Davis Built a Career Connecting the Parts
A bench scientist became a global commercial operator by learning to translate across functions, countries and incentives. At UCB, Mike Davis has made integration less of a slogan and more of a job description.
Heather Balsley
From a teenage farmers-market job to the executive committee at IHG, Heather Balsley built a career by learning how small customer moments connect to a global commercial system.
Xuandai Nguyen
Xuandai Nguyen, Ph.D., MBA, is Vice President, Head of Global Program Strategy and Chief of Staff to the CEO at Beacon Therapeutics, an ophthalmic gene therapy company working to restore sight in people with inherited and prevalent retinal diseases. A scientist-turned-strategist, Nguyen has spent more than two decades moving medicines from bench to market, with senior roles at Genentech, Forma Therapeutics and ACELYRIN spanning immunology, ophthalmology, respiratory and sickle cell disease. Trilingual and Berkeley- and Cornell-trained, Nguyen sits at the intersection of hard science and commercial strategy, translating complicated biology into the plans that decide which therapies reach patients.
Thomas Arnold
Thomas (Tom) Arnold is the Chief Executive Officer of ViCentra, the Dutch maker of Kaleido, billed as one of the smallest, lightest and most precise insulin patch pumps in its class. Appointed in February 2025 after nearly 25 years across Medtronic, PROCEPT BioRobotics, Boston Scientific and Sorin Group, he is steering ViCentra's smartphone-controlled automated insulin delivery system into European markets and toward a US entry, backed by financing that has grown from $85M to $98M.